排序方式: 共有69条查询结果,搜索用时 0 毫秒
11.
The stress of parturition in the dairy cow is associated with increased susceptibility to infectious disease. During the periparturient period the demands for calcium are increased; these increased demands for calcium can result in subclinical or clinical hypocalcemia. Periparturient cows also experience significant immune suppression. Because intracellular calcium signaling is a key early feature in immune cell activation, we have hypothesized that the increased demand for calcium in periparturient cows may adversely affect intracellular calcium stores of immune cells. This reduction in intracellular calcium stores in immune cells could blunt intracellular calcium release following an activating stimulus, contributing to the immune suppression seen in these animals. To test this hypothesis, peripheral mononuclear cells were obtained from 27 multiparous dairy cows spanning a period of 2 wk before and 2 wk after parturition. Following activation of these cells by anti-CD3 antibodies plus secondary antibodies, intracellular calcium release from intracellular stores was measured. The intracellular calcium released in response to the activation signal declined as calcium demand for lactation became more intense and recovered as plasma calcium normalized. Intracellular calcium stores in peripheral mononuclear cells, estimated by pretreating cells with pervanadate and ionomycin, significantly decreased at parturition and returned to normal levels as the cows’ blood calcium returned to normal levels. Hypocalcemia, which is common in periparturient dairy cows, is associated with decreased intracellular calcium stores in peripheral mononuclear cells. Our data suggest that this is the cause of a blunted intracellular calcium release response to an immune cell activation signal. It is concluded that intracellular Ca stores decrease in peripheral blood mononuclear cells (PBMC) before parturition and development of hypocalcemia. This suggests that systemic calcium stress precedes measurable hypocalcemia, particularly in cows that will develop milk fever. Therefore, PBMC intracellular Ca stores are a more sensitive measure of calcium stresses in transition cow. This decrease in PBMC intracellular Ca stores before parturition and the development of hypocalcemia contributes to periparturient immune suppression. 相似文献
12.
13.
14.
Polycystic ovary syndrome (PCOS) is a major anovulatory infertility affecting a great proportion of women of childbearing age and is associated with obesity, insulin resistance and chronic inflammation. Poor endometrial receptivity and recurrent implantation failure are major hurdles to the establishment of pregnancy in women with PCOS. The accumulating body of evidence obtained from experimental and clinical studies suggests a link between inherent adaptive and innate immune irregularities and aberrant endometrial features in PCOS. The use of conventional therapeutic interventions such as lifestyle modification, metformin and ovarian stimulation has achieved limited clinical success in restoring ovulation and endometrial receptivity in women with PCOS. Unlike other immunosuppressive drugs prescribed in the clinical management of autoimmune and inflammatory disorders that may have deleterious effects on fertility and fetal development, preclinical studies in mice and in women without PCOS but with repeated implantation failure revealed potential therapeutic benefits for the use of low-dose tacrolimus in treating female infertility. Improved systemic and ovarian immune functions, endometrial progesterone receptor and coreceptor expressions and uterine vascular adaptation to pregnancy were among features of enhanced progesterone-receptor sensitivity in the low-dose tacrolimus-treated mouse model of the disease. In this review, we have compiled available experimental and clinical data in literature on endometrial progesterone resistance and current therapeutic options, as well as mechanisms of actions and reported outcomes relevant to the potential therapeutic benefits for the use of low-dose tacrolimus in treating PCOS-associated female infertility. 相似文献
15.
Angelica Pace Fabio Scirocchi Chiara Napoletano Ilaria Grazia Zizzari Luca DAngelo Antonio Santoro Marianna Nuti Hassan Rahimi Aurelia Rughetti 《International journal of molecular sciences》2022,23(11)
Despite diagnostic and therapeutic improvements, glioblastoma (GB) remains one of the most threatening brain tumor in adults, underlining the urgent need of new therapeutic targets. Lectins are glycan-binding proteins that regulate several biological processes through the recognition of specific sugar motifs. Lectins and their ligands are found on immune cells, endothelial cells and, also, tumor cells, pointing out a strong correlation among immunity, tumor microenvironment and vascularization. In GB, altered glycans and lectins contribute to tumor progression and immune evasion, shaping the tumor-immune landscape promoting immunosuppressive cell subsets, such as myeloid-derived suppressor cells (MDSCs) and M2-macrophages, and affecting immunoeffector populations, such as CD8+ T cells and dendritic cells (DCs). Here, we discuss the latest knowledge on the immune cells, immune related lectin receptors (C-type lectins, Siglecs, galectins) and changes in glycosylation that are involved in immunosuppressive mechanisms in GB, highlighting their interest as possible novel therapeutical targets. 相似文献
16.
Ines Papak Elbieta Chruciel Katarzyna Dziubek Magorzata Kurkowiak Zuzanna Urban-Wjciuk Tomasz Marjaski Witold Rzyman Natalia Marek-Trzonkowska 《International journal of molecular sciences》2022,23(13)
Natural killer cells are innate lymphocytes with the ability to lyse tumour cells depending on the balance of their activating and inhibiting receptors. Growing numbers of clinical trials show promising results of NK cell-based immunotherapies. Unlike T cells, NK cells can lyse tumour cells independent of antigen presentation, based simply on their activation and inhibition receptors. Various strategies to improve NK cell-based therapies are being developed, all with one goal: to shift the balance to activation. In this review, we discuss the current understanding of ways NK cells can lyse tumour cells and all the inhibitory signals stopping their cytotoxic potential. 相似文献
17.
Justin Thomas Molly A. Torok Kriti Agrawal Timothy Pfau Trang T. Vu Justin Lyberger Hsiaochi Chang Alyssa Marie M. Castillo Min Chen Bryan Remaily Kyeongmin Kim Zhiliang Xie Mary E. Dillhoff Samuel K. Kulp Gregory K. Behbehani Zobeida Cruz-Monserrate Latha P. Ganesan Dwight H. Owen Mitch A. Phelps Christopher C. Coss Thomas A. Mace 《International journal of molecular sciences》2022,23(13)
The neonatal Fc receptor (FcRn) is responsible for recycling of IgG antibodies and albumin throughout the body. This mechanism has been exploited for pharmaceutic delivery across an array of diseases to either enhance or diminish this function. Monoclonal antibodies and albumin-bound nanoparticles are examples of FcRn-dependent anti-cancer therapeutics. Despite its importance in drug delivery, little is known about FcRn expression in circulating immune cells. Through time-of-flight mass cytometry (CyTOF) we were able to characterize FcRn expression in peripheral blood mononuclear cell (PBMC) populations of pancreatic ductal adenocarcinoma (PDAC) patients and non-cancer donors. Furthermore, we were able to replicate these findings in an orthotopic murine model of PDAC. Altogether, we found that in both patients and mice with PDAC, FcRn was elevated in migratory and resident classical dendritic cell type 2 (cDC2) as well as monocytic and granulocytic myeloid-derived suppressor cell (MDSC) populations compared to tumor-free controls. Furthermore, PBMCs from PDAC patients had elevated monocyte, dendritic cells and MDSCs relative to non-cancer donor PBMCs. Future investigations into FcRn activity may further elucidate possible mechanisms of poor efficacy of antibody immunotherapies in patients with PDAC. 相似文献
18.
通过构建含PD-1抗体基因的重组腺病毒表达载体Ad35-anti-PD-1,表达的PD-1抗体以探究其对细胞毒性T淋巴细胞(cytotoxic T lymphocyte,CTL)抗肿瘤功能的影响。用ELISA实验检测Ad35-anti-PD-1在293细胞中PD-1抗体的表达量;利用Protein G亲和层析法纯化PD-1抗体;通过体外杀伤实验研究PD-1抗体阻断PD-1信号通路的CTL杀伤肝癌细胞能力的变化。显示成功构建重组腺病毒载体Ad35-anti-PD-1,滴度为1×1010 pfu/mL;ELISA实验检测在72h时293细胞上清中PD-1抗体的表达量约在600ng/mL;Westernblotting实验证明PD-1抗体包含正确的重链(50kD)和轻链(25kD);ELISA实验检测从100mL细胞上清中得到1mL浓度在40μg/mL的PD-1抗体;体外杀伤实验证明CTL在添加PD-1抗体的环境中杀伤肝癌细胞的能力显著增强。 相似文献
19.
Gianluigi Zaza Simona Granata Paola Tomei Alessandra Dalla Gassa Antonio Lupo 《International journal of molecular sciences》2015,16(2):4281-4305
Renal transplantation represents the most favorable treatment for patients with advanced renal failure and it is followed, in most cases, by a significant enhancement in patients’ quality of life. Significant improvements in one-year renal allograft and patients’ survival rates have been achieved over the last 10 years primarily as a result of newer immunosuppressive regimens. Despite these notable achievements in the short-term outcome, long-term graft function and survival rates remain less than optimal. Death with a functioning graft and chronic allograft dysfunction result in an annual rate of 3%–5%. In this context, drug toxicity and long-term chronic adverse effects of immunosuppressive medications have a pivotal role. Unfortunately, at the moment, except for the evaluation of trough drug levels, no clinically useful tools are available to correctly manage immunosuppressive therapy. The proper use of these drugs could potentiate therapeutic effects minimizing adverse drug reactions. For this purpose, in the future, “omics” techniques could represent powerful tools that may be employed in clinical practice to routinely aid the personalization of drug treatment according to each patient’s genetic makeup. However, it is unquestionable that additional studies and technological advances are needed to standardize and simplify these methodologies. 相似文献
20.
Ru‐Huei Fu Shih‐Ping Liu Ching‐Liang Chu Ya‐Hsien Lin Yu‐Chen Ho Shao‐Chih Chiu Wei‐Yong Lin Woei‐Cherng Shyu Shinn‐Zong Lin 《Journal of the science of food and agriculture》2013,93(1):76-84
BACKGROUND: Myricetin is a naturally occurring flavonoid that is found in many fruits, vegetables, teas and medicinal herbs. It has been demonstrated to have anti‐inflammatory properties, but, to date, no studies have described the immunomodulatory effects of myricetin on the functions of dendritic cells (DCs). The aim of this study was to evaluate the potential for myricetin to modulate lipopolysaccharide (LPS)‐stimulated activation of mouse bone marrow‐derived DCs. RESULTS: Our experimental data showed that treatment with myricetin up to 10 µg mL−1 does not cause cytotoxicity in cells. Myricetin significantly decreased the secretion of tumour necrosis factor‐α, interleukin‐6 and interleukin‐12p70 by LPS‐stimulated DCs. The expression of LPS‐induced major histocompatibility class II, CD40 and CD86 on DCs was also inhibited by myricetin, and the endocytic and migratory capacity of LPS‐stimulated DCs was blocked by myricentin. In addition, LPS‐stimulated DC‐elicited allogeneic T‐cell proliferation was reduced by myricetin. Moreover, our results confirmed that myricetin attenuates the responses of LPS‐stimulated activation of DCs via suppression of IκB kinase/nuclear factor‐κB and mitogen‐activated protein kinase‐dependent pathways. CONCLUSION: Myricetin has novel immunopharmacological activity, and modulation of DCs by myricetin may be an attractive strategy for the treatment of inflammatory and autoimmune disorders, and for transplantation. Copyright © 2012 Society of Chemical Industry 相似文献